A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer
Latest Information Update: 29 Feb 2024
At a glance
- Drugs Vudalimab (Primary)
- Indications Carcinoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Urogenital cancer
- Focus Therapeutic Use
- Sponsors Xencor
- 27 Feb 2024 According to a Xencor media release, the company plans to continue enrollment and provide a data update and decision whether to advance vudalimab as a monotherapy for patients with mCRPC in the first half of 2025.
- 27 Feb 2024 Results (n=14) published in the Xencor Media Release
- 10 Oct 2023 Planned End Date changed from 31 Aug 2023 to 30 May 2025.